Last updated: May 26, 2026
What companies supply PITOCIN oxytocin injection in the US?
PITOCIN is the branded oxytocin injection product marketed in the US. The immediate “supplier” question splits into three supply layers: (1) oxytocin API manufacturers, (2) drug product manufacturers (filling/finishing), and (3) label holders and distributors operating under the FDA drug supply chain.
Key supply-layer takeaway
- “Suppliers” in practice means (a) FDA-registered manufacturers for the finished oxytocin injection and (b) label holders and distributors listed in FDA systems.
- For oxytocin injection, industry supply tends to include specialty sterile injectables sites with peptide handling capability and GMP sterile manufacturing capacity.
What is PITOCIN in FDA terms?
- Active ingredient: oxytocin
- Dosage form: injection (sterile, parenteral)
Which oxytocin API suppliers feed PITOCIN and other brands?
Oxytocin is a peptide hormone typically sourced through established peptide manufacturing suppliers. The API supply base for oxytocin injection generally consists of specialty peptide and active ingredient manufacturers that:
- synthesize oxytocin (peptide production, oxidation and folding steps),
- control for disulfide formation and impurities,
- deliver peptide API with documented specs suitable for sterile injectables.
Supply risk pattern for peptide APIs
- Oxytocin supply can tighten when peptide GMP capacity is constrained or when peptide suppliers face batch-release failures or raw material shortages.
- The API supply layer matters because formulation and fill-finish can be ready even when API release is delayed.
Who manufactures and fills the finished PITOCIN injection?
For finished sterile injectables, “supplier” usually means the cGMP manufacturing site(s) that perform:
- compounding/bulk preparation,
- aseptic filling (or terminal sterilization where applicable),
- lyophilized vs liquid sterile handling (PITOCIN is typically liquid injection),
- packaging and labeling under GMP.
How to map finished-product suppliers
- Use FDA labeling/manufacturer fields and FDA drug listing data to identify:
- manufacturer of record,
- packager,
- distributor/label holder.
What is the Orange Book status of PITOCIN oxytocin?
PITOCIN is an old, widely available peptide hormone. Oxytocin products typically have complex patent landscapes by formulation, manufacturing processes, and method-of-use. For a “supply” view, the more operational question is whether FDA lists reference product exclusivity, 505(b)(2) approvals, and current ANDA/abbreviated pathways for particular strengths/presentations.
Supplier implication
- When there are multiple approved versions across label holders and manufacturers, supply is distributed across more than one finished-product site.
Are there generic or interchangeable oxytocin injections that compete with PITOCIN?
Yes. Oxytocin injection is widely marketed as generics and as multiple label presentations. That matters for supply because:
- multiple approved products can reduce dependency on any single manufacturer for hospitals,
- contracting shifts among suppliers based on price, allocation, and availability.
What suppliers control US hospital oxytocin supply during shortages?
During supply constraints, distribution is driven by:
- which label holders can source API and sustain sterile fill capacity,
- which manufacturers can clear batch release without delays,
- which products are on national hospital group formularies and group purchasing organization contracts.
Operational supply levers
- allocation rules by distributors,
- lead times for peptide API release,
- shipping constraints for cold-chain or stability-controlled handling (when applicable).
Where do procurement teams get the “official supplier list” for PITOCIN?
Procurement lists usually pull from:
- FDA labeling/manufacturer-of-record fields for the specific NDC and strength,
- FDA drug facility registration databases (for sterile injectables sites),
- distributor listings for the supply chain under the Drug Supply Chain Security Act (DSCSA) framework.
Actionable procurement format
- Identify each NDC (strength and package size) for PITOCIN.
- For each NDC, capture:
- label holder,
- manufacturer of record,
- packager,
- distributor.
- Then map those to FDA-registered facilities for batch release oversight.
How does manufacturing geography affect PITOCIN supply continuity?
Oxytocin supply continuity depends on:
- local sterile fill-finish capacity,
- peptide synthesis robustness and raw material inputs,
- regulatory inspection outcomes that can halt or slow manufacturing.
Geography risk factors
- prolonged GMP remediation,
- sterile facility staffing constraints,
- backlog at QC release laboratories.
What patent or regulatory factors affect who can supply PITOCIN-like products?
Oxytocin itself is mature; regulatory barriers to generic supply are typically limited compared with newer biologics. Supply constraints are more often practical than legal:
- sterile manufacturing capacity,
- API availability,
- batch-release quality events.
Method-of-use and formulation patents can affect certain presentations, but the day-to-day supplier market for oxytocin injection is usually driven by manufacturing and approval status by NDC.
What commercial dynamics determine which supplier wins PITOCIN contracts?
Hospital group procurement and wholesalers prioritize:
- consistent in-stock performance,
- predictable lead times,
- allocation fairness during shortages,
- willingness to support contract pricing and emergency supply.
Contract determinants
- supply reliability of the fill-finish site,
- number of qualified NDC presentations available (backup SKUs),
- distributor service level and allocation strategy.
Comparison: PITOCIN supplier map vs oxytocin generics supplier map
Branded PITOCIN
- Fewer label SKUs, concentrated manufacturer relationships.
- Contracting may track label holder and main distributor.
Generic/multiple label oxytocin products
- More diversified manufacturing footprints.
- More sourcing options for procurement teams.
Procurement implication
- With multiple interchangeable generics, switching can be faster if NDCs remain clinically and operationally substitutable.
Key Takeaways
- For PITOCIN, “suppliers” should be mapped across API supply, finished sterile manufacturing/fill-finish, and label/distribution layers.
- Oxytocin injection supply is generally competitive through multiple manufacturers, so procurement can reduce risk by switching among approved NDCs rather than relying on a single brand channel.
- The most actionable supplier list is the NDC-level mapping of label holder, manufacturer of record, packager, and distributor using FDA labeling and facility registration sources.
FAQs
1) How do I identify the current PITOCIN manufacturer for a specific NDC?
Use the PITOCIN package labeling for that exact NDC strength and package size to capture label holder, manufacturer of record, and packager, then cross-check with FDA facility registration.
2) What drives oxytocin injection supply shortages in the US?
API release delays, sterile fill-finish capacity constraints, QC batch-release failures, and inspection-driven operational downtime.
3) Can hospitals substitute PITOCIN with generic oxytocin injection?
Typically yes for oxytocin injection products when the same active ingredient, dosage form, strength, and labeling requirements are met, guided by formulary policy and interchangeability.
4) What information matters most in supplier qualification for sterile peptide injectables like oxytocin?
Aseptic/sterile GMP capability, peptide handling and disulfide control, batch release track record, and ability to maintain stable supply without repeated allocation events.
5) How do DSCSA and FDA records support traceability for PITOCIN supply chains?
They support chain-of-custody data through distributor and trading-partner reporting aligned to DSCSA requirements, using FDA drug listing and product labeling for manufacturer mapping.
References
- U.S. Food and Drug Administration. “Drug Registration and Listing System (DRLS).” FDA.
- U.S. Food and Drug Administration. “National Drug Code (NDC) Directory.” FDA.
- U.S. Food and Drug Administration. “FDA Labeling (Drugs@FDA).” FDA.
